{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:27:53Z","timestamp":1762522073138,"version":"3.37.3"},"reference-count":72,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2017.07.099","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T18:30:44Z","timestamp":1501871444000},"page":"5442-5448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Herpes zoster prevention: A difficult problem to solve"],"prefix":"10.1016","volume":"36","author":[{"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Principi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.07.099_b0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.099_b0010","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/infdis\/171.3.701","article-title":"Racial differences in the occurrence of herpes zoster","volume":"171","author":"Schmader","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0015","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annepidem.2005.12.002","article-title":"Gender as an independent risk factor for herpes zoster: a population-based prospective study","volume":"16","author":"Opstelten","year":"2006","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.vaccine.2017.07.099_b0020","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(02)09837-9","article-title":"Contacts with varicella or with children and protection against herpes zoster in adults: a case\u2013control study","volume":"360","author":"Thomas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.07.099_b0025","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0030","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.099_b0035","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw205","article-title":"Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis","volume":"3","author":"Marra","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0040","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2017.07.099_b0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jinf.2016.05.008","article-title":"The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013","volume":"73","author":"Hobbelen","year":"2016","journal-title":"J. Infect."},{"key":"10.1016\/j.vaccine.2017.07.099_b0050","doi-asserted-by":"crossref","first-page":"e0125025","DOI":"10.1371\/journal.pone.0125025","article-title":"Increasing trends of herpes zoster in Australia","volume":"10","author":"Macintyre","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.vaccine.2017.07.099_b0055","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1016\/j.vaccine.2013.09.018","article-title":"Shingles in Alberta: before and after publicly funded varicella vaccination","volume":"32","author":"Russell","year":"2014","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2017.07.099_b0060","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/cid\/ciq077","article-title":"Herpes zoster incidence among insured persons in the United States, 1993\u20132006: evaluation of impact of varicella vaccination","volume":"52","author":"Leung","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0065","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/jmv.21599","article-title":"Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture","volume":"81","author":"Toyama","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.07.099_b0070","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1086\/430325","article-title":"Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992\u20132002","volume":"191","author":"Jumaan","year":"2005","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2017.07.099_b0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S095026880400281X","article-title":"Incidence of herpes zoster, 1997\u20132002","volume":"133","author":"Mullooly","year":"2005","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2017.07.099_b0080","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198209000-00003","article-title":"Population-based study of herpes zoster and its sequelae","volume":"61","author":"Ragozzino","year":"1982","journal-title":"Med (Baltimore)"},{"key":"10.1016\/j.vaccine.2017.07.099_b0085","doi-asserted-by":"crossref","first-page":"739","DOI":"10.7326\/0003-4819-159-11-201312030-00006","article-title":"Examination of links between herpes zoster incidence and childhood varicella vaccination","volume":"159","author":"Hales","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2017.07.099_b0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12877-017-0420-9","article-title":"The temporal impact of aging on the burden of herpes zoster","volume":"17","author":"Varghese","year":"2017","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.vaccine.2017.07.099_b0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/ciw296","article-title":"Increasing incidence of herpes zoster over a 60-year period from a population-based study","volume":"63","author":"Kawai","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0100","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4065\/84.9.787","article-title":"Health care utilization and cost burden of herpes zoster in a community population","volume":"84","author":"Yawn","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2017.07.099_b0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12879-017-2185-3","article-title":"Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia","volume":"17","author":"Friesen","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0110","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","article-title":"Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.099_b0115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0190-9622(98)70207-5","article-title":"Lasting immunity to varicella in doctors study (L.I.V.I.D. study)","volume":"38","author":"Solomon","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2017.07.099_b0120","doi-asserted-by":"crossref","first-page":"e66485","DOI":"10.1371\/journal.pone.0066485","article-title":"Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review","volume":"8","author":"Ogunjimi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.07.099_b0125","doi-asserted-by":"crossref","first-page":"e60732","DOI":"10.1371\/journal.pone.0060732","article-title":"Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries","volume":"8","author":"Poletti","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.07.099_b0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jdv.13957","article-title":"European consensus-based (S2k) Guideline on the Management of Herpes Zoster \u2013 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment","volume":"31","author":"Werner","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.vaccine.2017.07.099_b0135","unstructured":"Food and Drug Administration. Zostavax. Available at: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm132831.pdf. Accessed on: April 21, 2017."},{"key":"10.1016\/j.vaccine.2017.07.099_b0140","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4161\/hv.6.11.12852","article-title":"Concomitant administration of zoster and pneumococcal vaccines in adults \u226560years old","volume":"6","author":"MacIntyre","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.07.099_b0145","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1345\/aph.1R742","article-title":"Concomitant administration of pneumococcal-23 and zoster vaccines provides adequate herpes zoster coverage","volume":"47","author":"Wyman","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.vaccine.2017.07.099_b0150","unstructured":"Centers for Disease Control and prevention (CDC). Shingles\/Herpes Zoster Vaccine Recommendations. Available at: https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/recommendations.html. Accessed on: April 20, 2017."},{"key":"10.1016\/j.vaccine.2017.07.099_b0155","unstructured":"EUNETHTA. Zostavax for the prevention of herpes zoster and postherpetic neuralgia. Available at: http:\/\/www.eunethta.eu\/sites\/default\/files\/sites\/5026.fedimbo.belgium.be\/files\/Zostavax%20for%20prevention%20of%20herpes%20zoster%20and%20postherpetic%20neuralgia_Rapid%20REA_Final_Sep%202013_0.pdf. Accessed on: April 20, 2017."},{"key":"10.1016\/j.vaccine.2017.07.099_b0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/21645515.2017.1264831","article-title":"Prevention of Herpes Zoster and its complications: from clinical evidence to real life experience","volume":"13","author":"Gabutti","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.07.099_b0165","unstructured":"Ministero della Salute. Poano Nazionale Prevenzione Vaccinale 2\u201917-2019. Available at: http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2571_allegato.pdf. Accessed on: July 5, 2017."},{"key":"10.1016\/j.vaccine.2017.07.099_b0170","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/cid\/ciu501","article-title":"Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations","volume":"59","author":"Oxman","year":"2014","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2017.07.099_b0175","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/ciu498","article-title":"Vaccination against zoster remains effective in older adults who later undergo chemotherapy","volume":"59","author":"Tseng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.07.099_b0185","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0190","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Irwin","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0195","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/529043","article-title":"Primary vaccine failure after 1 dose of varicella vaccine in healthy children","volume":"197","author":"Michalik","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00006454-200204000-00014","article-title":"Inverse relationship between six week post-vaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection","volume":"21","author":"Li","year":"2002","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2017.07.099_b0205","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2017.07.099_b0210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jama.1984.03350030023016","article-title":"Live attenuated varicella vaccine. Efficacy for children with leukemia in remission","volume":"252","author":"Gershon","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.07.099_b0215","unstructured":"Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2007;56(RR-4):1\u201340."},{"key":"10.1016\/j.vaccine.2017.07.099_b0220","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1385\/CRIAI:19:2:183","article-title":"X-linked agammaglobulinemia","volume":"19","author":"Conley","year":"2000","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.vaccine.2017.07.099_b0225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jmv.1890270209","article-title":"Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster","volume":"27","author":"Webster","year":"1989","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.07.099_b0230","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/infdis\/152.6.1172","article-title":"Infection with varicella-zoster virus after marrow transplantation","volume":"152","author":"Locksley","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0235","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/infdis\/141.4.479","article-title":"Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant","volume":"141","author":"Meyers","year":"1980","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0240","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1086\/514077","article-title":"Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine","volume":"176","author":"Redman","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0245","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants","volume":"347","author":"Hata","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.099_b0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/jiv480","article-title":"Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults","volume":"213","author":"Levin","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.099_b0255","doi-asserted-by":"crossref","unstructured":"Gagliardi ANZ, Andriolo BNG, Torloni MR, Soares BGO. Vaccines for preventing herpes zoster in older adults. Cichrane Databas of Systematic Reviews 2016, Issue 3, Art. No.: CD008858.","DOI":"10.1002\/14651858.CD008858.pub3"},{"key":"10.1016\/j.vaccine.2017.07.099_b0260","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2017.07.099_b0265","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2017.07.099_b0270","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2017.07.099_b0275","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2017.07.099_b0280","doi-asserted-by":"crossref","unstructured":"Izurieta HS, Wernecke M, Kelman J, Wong S, Forshee R, Pratt D, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the medicare population ages 65 years and older. Clin Infect Dis 2017;64:785\u201393.","DOI":"10.1093\/cid\/ciw854"},{"key":"10.1016\/j.vaccine.2017.07.099_b0285","doi-asserted-by":"crossref","first-page":"e1001420","DOI":"10.1371\/journal.pmed.1001420","article-title":"Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study","volume":"10","author":"Langan","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.07.099_b0290","doi-asserted-by":"crossref","unstructured":"Yun H, Xie F, Baddley JW, Winthrop K, Saag KG, Curtis JR. Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol 2017 Mar 15. pii: jrheum.160685. http:\/\/dx.doi.org\/10.3899\/jrheum.160685 [Epub ahead of print].","DOI":"10.3899\/jrheum.160685"},{"key":"10.1016\/j.vaccine.2017.07.099_b0295","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.amepre.2016.08.029","article-title":"Herpes zoster vaccine coverage in older adults in the U.S., 2007\u20132013","volume":"52","author":"Zhang","year":"2017","journal-title":"Am J Prev Med"},{"issue":"355","key":"10.1016\/j.vaccine.2017.07.099_b0300","doi-asserted-by":"crossref","first-page":"i6604","DOI":"10.1136\/bmj.i6604","article-title":"Shingles vaccine coverage for 70year olds is falling","volume":"8","author":"Mayor","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.07.099_b0305","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s40588-016-0044-4","article-title":"Varicella-zoster virus glycoproteins: entry, replication, and pathogenesis","volume":"3","author":"Oliver","year":"2016","journal-title":"Curr Clin Microbiol Rep"},{"key":"10.1016\/j.vaccine.2017.07.099_b0310","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2017.07.099_b0315","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.099_b0320","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.099_b0325","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.099_b0330","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.099_b0335","doi-asserted-by":"crossref","unstructured":"Poder A, Geeraerts B, Lal H, Oostvogels L, Vanden Abeele C, Heineman TC. Immunogenicity and safety of 2 doses of an investigational herpes zoster subunit vaccine administered 2, 6 or 12 months apart in adults 50 years and older: results of a Phase III, randomized, open-label, multicenter trial. Presented at: ID Week 2016, October 26-30, New Orleans, Lu, Poster 753.","DOI":"10.1093\/ofid\/ofw172.616"},{"key":"10.1016\/j.vaccine.2017.07.099_b0340","doi-asserted-by":"crossref","unstructured":"Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Godeaux O, et al. Randomized, Phase III clinical trial to assess the immunogenicity and safety of an investigational subunit adjuvanted herpes zoster vaccine co-administered with a seasonal quadrivalent inactivated influenza vaccine in adults aged 50 years and older. Presented at: ID Week 2016, October 26-30, New Orleans, Lu, Poster 751.","DOI":"10.1093\/ofid\/ofw172.614"},{"key":"10.1016\/j.vaccine.2017.07.099_b0345","doi-asserted-by":"crossref","unstructured":"Tseng HF, Luo Y, SY L, Tartof S, Hechter R, Jacobsen S. No increased risk of herpes zoster after concomitant administration of zoster vaccine and pneumococcal polysaccharide vaccine. Presented at: ID Week 2016, October 26-30, New Orleans, Lu, Poster 752.","DOI":"10.1093\/ofid\/ofw172.615"},{"key":"10.1016\/j.vaccine.2017.07.099_b0350","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2017.07.099_b0355","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1017\/S0266462316000337","article-title":"Cost-effectiveness analysis of herpes zoster vaccination in Italian elderly persons","volume":"32","author":"Coretti","year":"2016","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vaccine.2017.07.099_b0360","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.vaccine.2016.10.055","article-title":"Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies","volume":"35","author":"Parrino","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T21:56:52Z","timestamp":1569967012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17310356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":72,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X17310356"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.099","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herpes zoster prevention: A difficult problem to solve","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}